Serotonin 5-HT2 receptor antagonists: Potential in the treatment of psychiatric disorders

CNS Drugs

Volumn 7, Issue 5, 1997, Pages 388-409

  Stefanski, Roman ^a   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXYTRYPTAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA METHYLSEROTONIN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; KETANSERIN; MIRTAZAPINE; NEFAZODONE; RISPERIDONE; RITANSERIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HORMONE RESPONSE; NEUROMODULATION; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SLEEP; TREATMENT OUTCOME;

EID: 0030966838     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707050-00006     Document Type: Review

References (225)

1. Peroutka SJ. 5-HT receptors: past, present and future. Trends Neurosci 1995; 18: 68-9
2. 2 receptor subtypes: a family re-united? Trends Pharmacol Sci 1995; 16: 105-9
3. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology 1994; 33: 275-317
4. Martin GR, Humphrey PPA. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 1994; 33: 261-73
5. 2 and stomach fundusa serotonin receptor genes. Neuroreport 1992; 3: 345-8
6. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563-76
7. Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 1985; 346: 231-49
8. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21: 123-39
9. 2 recognition sites. Brain Res 1986; 376: 97-107
10. 2 receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res 1987; 421: 263-79
11. 2 receptors in the rat median prefrontal cortex. J Pharmacol Exp Ther 1990; 252: 171-8
12. Mantz J, Godbout R, Tassin JP, et al. Inhibition of spontaneous and evoked unit activity in the rat medial prefrontal cortex by mesencephalic raphe nuclei. Brain Res 1990; 524: 22-30
13. 2 receptors. Eur J Pharmacol 1988; 145: 31-8
14. 2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol 1988; 153: 89-95
15. Muramatsu M, Tomaki-Ohashi J, Usuki C, et al. Serotonin-2 receptor-mediated regulation of release of acetylcholine by minaprine in cholinergic nerve terminals of hippocampus of rat. Neuropharmacology 1988; 27: 603-9
16. 2 receptors. Eur J Pharmacol 1988; 154: 285-91
17. 2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 1990; 101: 568-9
18. Matthews WD, Smith CD. Pharmacological profile of a model for central serotonin receptor activation. Life Sci 1980; 26: 1397-403
19. Foguet M, Hoyer D, Pardo LA, et al. Cloning and functional expression of the rat stomach fundus serotonin receptor. EMBO J 1992; 11: 3481-7
20. 2B receptor. Mol Pharmacol 1994; 46: 227-34
21. 2C receptors. Br J Pharmacol 1995; 115: 622-8
22. Cohen ML, Schenck KW, Colbert W, et al. Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle. J Pharmacol ExpTher 1985; 232: 770-4
23. 2B) from rat stomach fundus. Mol Pharmacol 1992; 42: 549-57
24. Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: characterisation of a new type of serotonin recognition site. Eur J Pharmacol 1984; 106: 539-46
25. 1C receptor. Science 1988; 214: 558-64
26. 1C receptor mRNA in the rodent brain examined by in situ hybridisation histocheimstry. Comparison with receptor binding distribution. Neuroscience 1990; 35: 577-91
27. 1C receptors in rat choroid plexus. Brain Res 1987; 400: 396-8
28. Hartig PR. Molecular biology of 5-HT receptors. Trends Pharmacol Sci 1989; 10: 64-9
29. 1C receptor. J Pharmacol Exp Ther 1990; 254: 253-7
30. 1C receptors. Br J Pharmacol 1988; 94: 137-47
31. 1C receptors mediate mCPP-induced hypophagia. Br J Pharmacol 1991; 103: 2016-20
32. 1C receptor agonism as an initiating event in migraine. In: Olesen J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press Ltd., 1992: 200-12
33. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991; 30: 1139-66
34. 7) receptors. J Pharmacol ExpTher 1994; 268: 1403-10
35. De Boor T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57 Suppl. 4: 19-25
36. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995; 56 Suppl. 6: 3-11
37. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81-6
38. Cutler NR, Sramek JJ, Heppel Hesselink JM, et al. A doubleblind, placebo-controlled study comparing the efficacy, safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder. A prospective multicenter trial. J Clin Psychopharmacol 1993; 13: 429-37
39. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 1995; 66: 319-95
40. Barrett JE, Vanover KE. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology 1993; 112: 1-12
41. Chopin P, Briley M. Animal models of anxiety: the effect of compounds that modify serotonergic function. Trends Pharmacol Sci 1987; 8: 383-8
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
43. Rodgers RJ, Cole JC, Cobain MR, et al. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plusmaze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 1992; 3: 621-34
44. 1C receptor antagonists. Eur J Pharmacol 1989; 164: 445-54
45. Klodzinska A, Jaros T, Chojnacka-Wojcik E, et al. Exploratory hypoactivity induced by m-trifluoromethylpiperazine (TFMPP) and m-chlorophenylpiperazine (mCPP). J Neural Transm 1989; 1: 207-18
46. Kilts CD, Commissaris RL, Cordon JJ, et al. Lack of central 5-hydroxytryptamine influence on the anticonflict activity of diazepam. Psychopharmacology 1982; 78: 156-64
47. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology 1992; 107: 135-9
48. 2 receptors. Psychopharmacology 1987; 93: 502-6
49. Lucki I, Ward HR, Frazer A. Effects of 1-(m-chlorophenyl)piperazine and 1-(m- trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 1989; 249: 155-64
50. 1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology 1992; 107: 374-84
51. Witkin JM, Perez LA. Comparison of effects of buspirone and gepirone with benzodiazepines and antagonists of dopamine and serotonin receptors on punished behavior in rats. Behav Pharmacol 1989-1990; 1: 247-54
52. Amrick CL, Bennett DA. A comparison of the anticonflict activity of serotonin agonists and antagonists in rats [abstract]. Soc Neurosci Abstr 1986; 12: 907
53. Pellow S, Chopin P, File SE, et al. Validation of open closed arm entries in an elevated plus-maze as a measure of anxiety in rats. J Neurosci Methods 1985; 14: 149-67
54. 2 receptor downregulation results in anxiolytic effects in the elevated plus-maze test. Drug Dev Res 1992; 25: 287-97
55. File SE, Johnston AL, Pellow S. Effects of compounds acting at CNS 5-hydroxytryptamine systems on anxiety in the rat [abstract]. Br J Pharmacol 1987; 90 Suppl.: 265P
56. Wright IK, Heaton M, Upton N, et al. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the elevated X-maze. Psychopharmacology 1992; 107: 405-14
57. Tomkins DM, Costall B, Kelly ME. Action of ritanserin and DOI on the elevated X-maze [abstract]. Psychopharmacology 1990; 101: S57
58. Costall B, Domeney AM, Gerrard PA, et al. A primate model for the assessment of anxiolytic drug action [abstract]. Br J Pharmacol 1988; 95 Suppl.: 475P
59. Gao B, Cutler MG. Effects of acute and subchronic administration of ritanserin on the social behavior of mice. Neuropharmacology 1993; 32: 265-72
60. Colpaert FC, Meert TF, Niemegeers CJE, et al. Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rats. Psychopharmacology 1985; 86: 45-54
61. Meert TF, Colpaert FC. Effects of S2 antagonists in two conflict procedures that involve exploratory behaviour [abstract]. Psychopharmacology 1986; 89: S23
62. Stefanski R, Palejko W, Kostowski W, et al. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 1992; 31: 1251-8
63. Brocco MJ, Koek W, Degryse AD, et al. Comparative studies on the anti-punishment effects of chlordiazepoxide, huspirone and ritanserin in the pigeon Geller-Seifter and Vogel conflict procedures. Behav Pharmacol 1990; 1: 403-18
64. 2 receptor sensitivity in generalised anxiety disorder: a pilot study with ritanserin. Psychopharmacology 1992; 108: 387-9
65. 1 recognition sites. J Recept Res 1988; 8: 59-81
66. Hamik A, Peroutka SJ. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989; 25: 569-75
67. Kahn RS, Asnis GM, Wetzler S, et al. Neuroendocrine evidence for serotonin receptor supersensitivity in patients with panic disorder. Psychopharmacology 1988; 96: 360-4
68. Kahn RS, Wetzler S, van Praag HM, et al. Behavioral indications of serotonin receptor hypersensitivity in patients with panic disorder. Psychiatry Res 1988; 25: 101-4
69. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology 1987; 92: 14-24
70. Germine M, Goddard AW, Woods SW, et al. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992; 34: 457-61
71. Krystal JH, Southwick SM, Morgan CA, et al. Noradrenergic and serotonergic mechanisms in PTSD. Presented at: the Annual Meeting of the American College of Neuropsychopharmacology: 1991 Dec 8-13; San Juan, Puerto Rico
72. Zohar J, Insel TR, Zohar-Kadouch RC, et al. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45: 167-72
73. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992; 49: 21-8
74. Charney DS, Goodman WK, Price LH, et al. Serotonergic function in obsessive compulsive disorder: a comparison of the effects of tryptophan and mCPP in patients and healthy subjects. Arch Gen Psychiatry 1988; 45: 177-85
75. Pigott TA, Hill JL, Grady TA, et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP. Biol Psychiatry 1993; 33: 3-14
76. Pigott TA, Zohar J, Hill JL, et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 1991; 29: 418-26
77. 2 antagonist WY-50,324 in pigeons. Drug Dev Res 1991; 24: 179-88
78. 1C/2 antagonists as therapeutic agents. Drug News Perspect 1992; 5: 397-406
79. 2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon. J Pharmacol Exp Ther 1996; 276: 388-97
80. Ceulemans DLS, Hoppenbrouwers LJA, Gelders YG, et al. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985; 18: 303-5
81. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
82. Ceulemans DLS, Hoppenbrouwers LJA, Gelders YG, et al. The effect of benzodiazepine withdrawal on the therapeutic efficacy of a serotonin antagonist in anxiety disorders. IVth World Congress of Biological Psychiatry: 1985 Sep 9-14; Philadelphia, 58
83. Jansen AAI, Pangalilia-Ratu Langi EA. Ritanserin - an original thymosthenic in the treatment of generalized anxiety disorders [abstract]. Psychopharmacology 1988; 96 Suppl.: S350
84. 2 antagonist MDL 11,939 in patients with generalized anxiety disorders. J Clin Psychopharmacol 1995; 15: 20-2
85. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
86. Den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990; 102: 85-94
87. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York, Raven Press Ltd., 1995: 933-44
88. McKeith IG, Marshall EF, Ferrier IN, et al. 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord 1987; 13: 67-74
89. 2 and beta-adrenergic receptor binding in the frontal corticies of suicide victims. Arch Gen Psychiatry 1986; 43: 945-59
90. 2 changes in major depression. Biol Psychiatry 1990; 27: 489-96
91. 2 receptor binding sites in depressed suicide victims. Brain Res 1988; 443: 272-80
92. Crow TJ, Cross AJ, Cooper SJ, et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicide. Neuropharmacology 1984; 23: 1561-9
93. Lowther S, De Paermentier F, Crompton MR, et al. Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment. Brain Res 1994; 642: 281-9
94. Stahl SM. The human blood platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorder. Arch Gen Psychiatry 1977; 34: 509-16
95. 2 receptor binding on blood platelets a peripheral marker for depression? Life Sci 1987; 41: 2485-92
96. 2 receptor binding on blood platelets of suicidal men. Psychopharmacology 1990; 100: 165-7
97. Pandey GN, Pandey SC, Janicak PG, et al. Platelet serotonin-2 binding sites in depression and suicide. Biol Psychiatry 1990; 28: 215-22
98. Mikuni M, Kagaya A, Takahashi K, et al. Serotonin but not epinephrine-induced calcium mobilization of platelets is enhanced in affective disorders. Psychopharmacology 1992; 106: 311-4
99. Biegon A. Receptor studies in suicidal patients. In: Racagni G, Brunello N, Fukuda T, editors. Biological psychiatry. Vol. 1. Amsterdam: Elsevier Science Publishers B. V., 1991: 103-5
100. 2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology 1990; 102: 73-5
101. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 1980; 210: 88-90
102. Kellar KJ, Caseio CS, Butler JA, et al. Different effect of electroconvulsive shock and antidepressant drugs on serotonin-2 receptors in rat brain. Eur J Pharmacol 1981; 69: 515-8
103. Treiser S, Kellar KJ. Lithium effects on serotonin receptors in rat brain. Eur J Pharmacol 1980; 64: 183-5
104. Wajda IJ, Banay-Schwartz M, Maigault I, et al. Modulation of the serotonin S-2 receptor in brain after chronic lithium. Neurochem Res 1986; 11: 949-57
105. Nelson DR, Thomas DR, Johnson AM. Pharmacological effects of paroxetine after repeated administration to animals. Acta Psychiatr Scand 1989; 80 Suppl. 350: 21-3
106. 2-mediated behavior in the rat following noradrenergic or serotonergic denervation. J Neural Transm Gen Sect 1991; 84: 19-32
107. 3H]spiperone binding in rat frontal cortex and serotonin receptor mediated behavior. Psychopharmacology 1983; 80: 150-5
108. 2 receptor binding sites. Drug Dev Res 1991; 24: 93-105
109. Leysen JL, Van Gompel P, Commeren W, et al. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology 1986; 88: 434-44
110. Vetulani J, Lehrecht U, Pile A. Enhancement of responsiveness of central serotonergic system and serotonin-2 receptor density in rat frontal cortex by electroconvulsive treatment. Eur J Pharmacol 1981; 76: 81-5
111. Wamsley JK, Byerley WF, McCabe RT, et al. Receptor alteration associated with serotonergic agents: an autoradiographic analysis. J Clin Psychiatry 1987; 48 Suppl.: 19-25
112. 2 receptors in rat brain: an autoradiographic study. Synapse 1993; 14: 324-31
113. Hyttel J, Overo KF, Arnt J. Biochemical effects and drug levels in rats after long term treatment with the specific 5-HT uptake inhibitor, citalopram. Psychopharmacology 1984; 83: 20-7
114. 2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 1992; 86: 133-7
115. Pranzatelli MR, Eng B. Chronic ACTH treatment: influence on 5-HT2 receptors and behavioral supersensitivity induced by 5,7-dihydroxytryptamine lesions. Peptides 1989; 10: 5-8
116. 2 receptor-mediated wet-dog shake behaviors. Psychopharmacology 1992; 108: 27-32
117. Cowen PJ, Anderson IM, Gartside SE. Endocrinological responses to 5-HT. Ann NY Acad Sci 1990; 600: 250-9
118. Van de Kar LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol 1991; 31: 289-320
119. Tuomisto J, Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985; 37: 249-332
120. 3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology 1992; 55: 336-43
121. Levy AD, Van de Kar LD. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants. Life Sci 1992; 51: 83-94
122. 2 agonist DOI. Eur J Pharmacol 1989; 161: 42-52
123. 1A receptors. Br J Pharmacol 1990; 100: 793-9
124. Berendsen HHG, Broekkamp CLE. Behavioral evidence for functional interactions between 5-HT receptor subtypes in rats and mice. Br J Pharmacol 1990; 101: 667-73
125. 2 receptors? Pharmacol Biochem Behav 1990; 36: 901-6
126. Yocca FD, Wright RN, Margraf RR, et al. 8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake responses in rats. Pharmacol Biochem Behav 1990; 35: 1-4
127. Meltzer HY, Maes M. Effect of pindolol on the L-5-HTP-induced increase in plasma prolaclin and cortisol concentrations in man. Psychopharmacology 1994; 114: 635-43
128. Murphy DL, Mitchell PB, Potter WZ. Novel pharmacological approaches to the treatment of depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacologv: the fourth generation of progress. New York: Raven Press Ltd., 1995: 1143-53
129. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-5
130. Marek GJ, Li AA, Seiden LS. Selective 5-hydroxytryptamine: antagonists have antidepressant-ike effects on differential-reinforcement-of-low-rate 72-second schedule. J Pharmacol Exp Ther 1984; 250: 52-9
131. 2 receptors. Hum Psychopharmacol 1986; 1: 93-7
132. Reyntjens AJM, Gelders YG, Hoppenbrouwers LJA, et al. Thymostenic effects of ritanserin (R55667), a centrally acting serotonin S-2 receptor blocker. Drug Dev Res 1986; 8: 205-11
133. 2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83: 244-8
134. Bakish D, Lapierre YD, Weinstein R, et al. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993; 13: 409-14
135. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 Suppl. 6: 12-21
136. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 Suppl. 6: 37-42
137. Feighner JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25: 219-21
138. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994; 164: 802-5
139. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234-41
140. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1995; 56 Suppl. 6: 30-6
141. Potter WZ. Adrenoceptor and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996; 57 Suppl. 4: 4-8
142. Goodwin GM, Edin FR. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996; 57 Suppl. 4: 9-13
143. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 20: 191-6
144. Bremner JD. A double-blind comparison of ORG 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56: 519-25
145. Laruelle M, Abi-Dargham A, Casanova MF, et al. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. Arch Gen Psychiatry 1993; 50: 810-8
146. 2 receptors in chronic schizophrenics. Biol Psychiatry 1986; 21: 1407-14
147. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 1991; 85: 19-29
148. Whitaker PM, Crow TJ, Ferrier IN. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 1981; 38: 278-80
149. Owen F, Cross AJ, Crow TJ, et al. Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand 1981; 63: 20-8
150. Joyce JN, Shane A, Lexow N, et al. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8: 315-36
151. 2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm 1984; 18 Suppl.: 273-7
152. Iqbal N, Asnis GM, Wetzler S, et al. The mCPP challenge test in schizophrenia: hormonal and behavioral responses. Biol Psychiatry 1991; 30: 770-8
153. Krystal JH, Seibyl JP, Price LH, et al. m-Chlorophenylpiperazine (MCPP) effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993; 50: 624-35
154. Krystal JH, Seibyl JP, Karper L, et al. Ritanserin blockade of M-CPP effects in schizophrenia [abstract NR429]. In: New research program and abstracts of the 145th annual meeting of the American Psychiatric Association; 1992 May 2-7; Washington, DC
155. Breier A, Kirkpatrick B, Buchanan RW. Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 1993; 34: 492-4
156. Kahn RS, Siever L, Davidson M, et al. Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology 1993; 112: S90-4
157. Roth BL, Meltzer HY. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, Ltd., 1995: 1215-27
158. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-9
159. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995; 273: 273-9
160. 2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990; 253: 1162-70
161. Hicks PB. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990; 47: 1609-15
162. Bethany S, Neal-Beliveau JN, Lucki J, et al. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993; 265: 207-17
163. 2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res 1995; 15: 153-4
164. 2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. J Pharmacol Exp Ther 1992; 260: 872-8
165. Grenhoff J, Che-Se T, Uqedo L, et al. Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 1990; 66 Suppl. 1: 29-33
166. 2 neurotransmission as revealed by selective antagonism of hyperactivity to tryptamine and apomorphine. J Pharmacol Exp Ther 1990; 254: 945-51
167. 2 receptors exert a state dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992; 223: 65-74
168. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-76
169. 2 receptors in antipsychotic activity. Life Sci 1995; 56: 2209-22
170. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990; 54: 1755-60
171. Youngren KD, Moghaddam B, Bunney BS, et al. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 1994; 165: 41-4
172. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18-27
173. Fuster JM. The prefrontal cortex. New York, NY: Raven Press, 1980
174. Weinberger DR. Schizophrenia and the frontal lobe. Trends Neurosci 1988; 11: 367-70
175. Wolkin A, Sanfilipo M, Wolf AP, et al. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 959-65
176. Deutch AT. The regulation of subcortical dopamine systems by the prefrontal cortex: interaction of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm 1992; 36 Suppl.: 61-89
177. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980; 286: 74-7
178. Leccese AP, Lyness WH. Lesions of dopamine neurons in the medial prefrontal cortex: effects on self administration of amphetamine and dopamine synthesis in the brain of the rat. Neuropharmacology 1987; 26: 1303-8
179. Haroutunian V, Knott P, Davis KL. Effects of mesocortical dopaminergic lesions upon subcortical dopaminergic function. Psychopharmacol Bull 1988; 24: 341-4
180. Deutch AY, Clark WA, Roth RH. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 1990; 521: 311-5
181. Rosin DL, Clark WA, Goldstein M, et al. Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in mesolimbic and nigrostriatal dopamine systems. Neuroscience 1992; 48: 8319
182. 2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993; 266: 684-91
183. Bunney BS, Walter JR, Roth RH, et al. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 1973; 185: 560-71
184. Goldstein JM, Litwin LC, Sutton EB, et al. Effects of ICI 169,369, a selective serotonin antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 1989; 249: 673-80
185. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T102C polymorphism of the 5 hydroxytryptamine type 2a-receptor gene. Lancet 1996; 347: 1294-6
186. Ceulemans DLS, Gelders YG, Hoppenbrouwers JA, et al. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 1985; 85: 329-32
187. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 1993; 163: 451-5
188. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13: 500-6
189. 2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373-6
190. Miller CH, Hummer M, Pycha K, et al. The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuro-Psychopharmacol Biol Psychiatry 1992; 16: 247-51
191. 2 receptor blocking agent. Curr Ther Res 1986; 40: 492-9
192. Wiesel F, Nordstrom AL, Farde L, et al. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994; 114: 31-8
193. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a douhle-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
194. Meltzer HY. Treatment of the neuroleptic non-responsive schizophrenic patients. Schiz Bull 1992; 18: 515-42
195. R-associated granulocytopenia: a review of the situation. Psychopharmacology 1989; 99 Suppl.: S118-21
196. 3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmacol 1990; 182: 465-72
197. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71-6
198. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 1991; 350: 614-9
199. Peroutka SJ, Snyder S. Relationship of neuropleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980; 137: 1518-22
200. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984; 103: 197-214
201. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 1991; 350: 614-9
202. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152: 1444-9
203. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-44
204. Farde L, Wiesel FA, Halldin C, et al. Central D-2 dopamine receptor occupancy in schizophrenic patients treated with anti-psychotic drugs. Arch Gen Psychiatry 1988; 45: 71-6
205. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 1989, 99: S28-31
206. 2 receptor binding in risperidone-treated schizophremc patients. J Clin Psychopharmacol 1995; 15 Suppl. 1: I9S-23S
207. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 1993; 110: 265-72
208. 2 dopamine receptor occupancy of risperidone and its relationship to extra-pyramidal symptoms: a PET study. Life Sci 1995; 57: PL 103-7
209. 2 receptor occupancy studies and clinical response. Br J Psychiatry 1996; 168 Suppl. 29: 40-4
210. 2 receptors and antipsychotic drugs studied with PET in schizophrenia: preliminary results [abstract]. Anales de Psiquiatria 1992; 8 Suppl. 1: 9
211. 2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996; 124: 35-9
212. 2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 685-93
213. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213-8
214. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295-305
215. Muller-Spahn R, for the International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992; 15 Suppl. 1, Pt A: 90A-1A
216. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment ot chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
217. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
218. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395-402
219. Klieser E, Lehman E, Kinzler E, et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15 Suppl. 1: 45S-51S
220. Bjerkenstedt L. Melperone in the treatment of schizophrenia. Acta Psychiatr Scand 1989; 80 Suppl. 352: 35-9
221. Bjork A, Bergman I, Gustavsson G. Amperozide in the treatment of schizophrenic patients: a preliminary report. In: Meltzer HY, editor. Novel atypical antipsychotic drugs. New York: Raven Press, 1992: 47-58
222. Christensson EG. Amperozide and some other atypical compounds with antipsychotic effect. In: Meltzer HY, editor. Novel atypical antipsychotic drugs. New York: Raven Press, 1992: 19-32
223. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine verses placebo: results of a double-blind, fixed-dose olazapine trial. Psychopharmacology 1996; 124: 159-67
224. Barnas C, Stuppack CH, Miller C, et al. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial vs. haloperidol. Int Clin Psychopharmacol 1992; 7: 23-7
225. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, doseranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-75